Johnson & Johnson: DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care?
Le Lézard

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and ...
Hosted on MSN

What Causes Water on the Knee (Knee Effusion) and How to Treat It

Water on the knee, or knee effusion, refers to the buildup of fluid in and around the knee joint. This condition leads to a painful, swollen knee and can be caused by various factors, including ...